- Conditions
- Neuroblastoma
- Interventions
- 131I-MIBG, Dinutuximab, Vorinostat, Sargramostim, Potassium Iodide
- Radiation · Drug
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 130
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metabolic Bone Disease
- Interventions
- Lanthanum Carbonate (Fosrenol), placebo
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma
- Interventions
- Carfilzomib, Bendamustine, Rituximab
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 3
- States / cities
- Davis, California • San Diego, California • San Francisco, California
- Conditions
- Anaplastic Thyroid Cancer, Thyroid Cancer, Differentiated Thyroid Cancer
- Interventions
- MLN0128
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 3
- States / cities
- Newport Beach, California • Boston, Massachusetts • Ann Arbor, Michigan
- Conditions
- Human Papillomavirus-Related Carcinoma, Human Papillomavirus Positive Oropharyngeal Carcinoma, Human Papillomavirus Positive Cervical Carcinoma, Human Papillomavirus Positive Anal Carcinoma, Human Papillomavirus Positive Vulvar Carcinoma, Human Papillomavirus Positive Penile Carcinoma
- Interventions
- HPV Specific T Cells, Cytoxan, Fludarabine, Nivolumab
- Genetic · Drug · Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hepatocellular Carcinoma
- Interventions
- GLYCAR T cells, Cytoxan, Fludarabine
- Genetic · Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma, Refractory Cancer, Colorectal Neoplasms
- Interventions
- Durvalumab, Tremelimumab, Pexa-Vec
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma
- Interventions
- AMP-224, Stereotactic Body Radiation Therapy(SBRT), Cyclophosphamide
- Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Multiple Myeloma
- Interventions
- Modakafusp Alfa, Daratumumab
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 13
- States / cities
- Gilbert, Arizona • Los Angeles, California • Fort Wayne, Indiana + 10 more
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Interventions
- AMXT1501, DFMO
- Drug
- Lead sponsor
- Aminex Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 4
- States / cities
- Austin, Texas • Houston, Texas • San Antonio, Texas + 1 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Pembrolizumab, Binimetinib, Oxaliplatin, Leucovorin, 5-Fluorouracil [5-FU], Irinotecan
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 10
- States / cities
- Duarte, California • Aurora, Colorado • New Haven, Connecticut + 7 more
- Conditions
- Breast Cancer Metastatic, Breast Cancer
- Interventions
- Olaparib, Vorinostat
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Obesity and Type 2 Diabetes
- Interventions
- 10 mg glipizide ingestion
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Liver Cancer, Rhabdomyosarcoma, Malignant Rhabdoid Tumor, Liposarcoma, Wilms Tumor, Yolk Sac Tumor
- Interventions
- CARE T cells
- Genetic
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2042
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- AZD2287, AZD2275, AZD2284
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 12
- States / cities
- Palo Alto, California • San Diego, California • Miami, Florida + 9 more
- Conditions
- Corneal Epithelial Degeneration
- Interventions
- TTHX1114(NM141) Ophthalmic Solution
- Drug
- Lead sponsor
- Trefoil Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma
- Interventions
- Carfilzomib, Rituximab, Cyclophosphamide, Doxorubicin hydrochloride, Vincristine sulfate, Prednisone, Pegfilgrastim, Acyclovir
- Drug · Biological
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 3
- States / cities
- Buffalo, New York • Cleveland, Ohio
- Conditions
- Lung Cancer, Head and Neck Cancer
- Interventions
- Panobinostat (LBH589), erlotinib
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Pancreatic Cancer
- Interventions
- Capecitabine, Docetaxel, Gemcitabine
- Drug
- Lead sponsor
- Tony Bekaii-Saab
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Columbus, Ohio
- Conditions
- NSCLC
- Interventions
- BMS-986315, Nivolumab, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 5
- States / cities
- Glendale, California • Clermont, Florida • Orange City, Florida + 2 more
- Conditions
- Glioblastoma
- Interventions
- B-cell vaccination
- Biological
- Lead sponsor
- Catalina Lee Chang
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
- Interventions
- BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide, Carboplatin, Paclitaxel, Topotecan
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 18
- States / cities
- Anchorage, Alaska • Los Angeles, California • Clermont, Florida + 15 more
- Conditions
- Recurrent Prostate Cancer
- Interventions
- ADXS-504
- Drug
- Lead sponsor
- Mark Stein
- Other
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Solid Tumor, Anaplastic Thyroid Cancer
- Interventions
- Crolibulin, Cisplatin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland